TY - JOUR
T1 - Portopulmonary hypertension and liver transplant
T2 - Recent review of the literature
AU - Cosarderelioglu, Caglar
AU - Cosar, Arif M.
AU - Gurakar, Merve
AU - Pustavoitau, Aliaksei
AU - Russell, Stuart D.
AU - Dagher, Nabil N.
AU - Gurakar, Ahmet
N1 - Publisher Copyright:
© Baskent University 2016 Printed in Turkey. All Rights Reserved.
PY - 2016/4
Y1 - 2016/4
N2 - Portopulmonary hypertension is one of the main pulmonary conditions affecting patients with liver disease and/or portal hypertension. Other conditions include hepatopulmonary syndrome and hepatic hydrothorax. Portopulmonary hypertension is caused by pulmonary vasoconstriction and increased pulmonary vascular resistance. It develops as a result of portal hypertension with or without liver disease and is associated with a higher morbidity and mortality. However, portopulmonary hypertension is usually asymptomatic; the most common symptoms are dyspnea, fatigue, and peripheral edema. All liver transplant candidates should be screened for potential portopulmonary hypertension because its coexistence can affect survival rates after transplant. All patients with cirrhosis who present with dyspnea should also be screened. Transthoracic echo - cardiography is a noni nvasive, useful method for screening, but right heart-sided catheterization remains the criterion standard for diagnosis. Portopulmonary hypertension carries a poor prognosis without liver transplant, and its severe form is considered to be a contraindication for liver transplant. Treating patients with pulmonary arterial hypertension-specific therapies before liver transplant for moderate and severe portopulmonary hyper - tension appears to be beneficial.
AB - Portopulmonary hypertension is one of the main pulmonary conditions affecting patients with liver disease and/or portal hypertension. Other conditions include hepatopulmonary syndrome and hepatic hydrothorax. Portopulmonary hypertension is caused by pulmonary vasoconstriction and increased pulmonary vascular resistance. It develops as a result of portal hypertension with or without liver disease and is associated with a higher morbidity and mortality. However, portopulmonary hypertension is usually asymptomatic; the most common symptoms are dyspnea, fatigue, and peripheral edema. All liver transplant candidates should be screened for potential portopulmonary hypertension because its coexistence can affect survival rates after transplant. All patients with cirrhosis who present with dyspnea should also be screened. Transthoracic echo - cardiography is a noni nvasive, useful method for screening, but right heart-sided catheterization remains the criterion standard for diagnosis. Portopulmonary hypertension carries a poor prognosis without liver transplant, and its severe form is considered to be a contraindication for liver transplant. Treating patients with pulmonary arterial hypertension-specific therapies before liver transplant for moderate and severe portopulmonary hyper - tension appears to be beneficial.
KW - Pulmonary complications of cirrhosis
UR - http://www.scopus.com/inward/record.url?scp=84962667244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962667244&partnerID=8YFLogxK
U2 - 10.6002/ect.2015.0351
DO - 10.6002/ect.2015.0351
M3 - Review article
C2 - 27015528
AN - SCOPUS:84962667244
SN - 1304-0855
VL - 14
SP - 113
EP - 120
JO - Experimental and Clinical Transplantation
JF - Experimental and Clinical Transplantation
IS - 2
ER -